Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis

被引:0
作者
Y. Xu
C. S. Yang
Y. J. Li
X. D. Liu
J. N. Wang
Q. Zhao
W. G. Xiao
P. T. Yang
机构
[1] First Affiliated Hospital,Department of Rheumatology and Immunology
[2] China Medical University,Department of 1st Cancer Institute
[3] First Affiliated Hospital,undefined
[4] China Medical University,undefined
来源
Clinical Rheumatology | 2016年 / 35卷
关键词
Amyopathic dermatomyositis; Biomarkers; Comorbidity; Rheumatic diseases;
D O I
暂无
中图分类号
学科分类号
摘要
Clinically amyopathic dermatomyositis (CADM) is a unique subset of dermatomyositis, showing a high incidence of lung involvements. The aim of this study is to identify risk factors, other than melanoma differentiation-associated protein (MDA)-5, for developing rapidly progressive-interstitial lung disease (RP-ILD) in patients with CADM. Forty CADM patients, in whom 11 patients developed RP-ILD, were enrolled. Clinical features and laboratory findings were compared between the patients with and without RP-ILD. We found that skin ulceration, CRP, serum ferritin, anti-MDA5 Ab, and lymphocytopenia were significantly associated with ILD. Multivariate logistic regression analysis indicated that anti-MDA5 Ab+, elevated CRP, and decreased counts of lymphocyte were independent risk factors for RP-ILD, which can provide a precise predict for RP-ILD in CADM patients. When anti-MDA5 Ab+ was removed from the multivariate regression model, using skin ulcerations, elevated serum ferritin and decreased counts of lymphocyte can also precisely predict RP-ILD. Except for MDA-5, more commonly available clinical characteristics, such as skin ulcerations, serum ferritin, and count of lymphocyte may also help to predict prognosis in CADM.
引用
收藏
页码:113 / 116
页数:3
相关论文
共 39 条
  • [1] Sontheimer RD(2002)Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46 626-636
  • [2] Gerami P(2006)A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies J Am Acad Dermatol 54 597-613
  • [3] Schope JM(2013)The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum Clin Exp Rheumatol 31 128-134
  • [4] McDonald L(2007)Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study Clin Rheumatol 26 1647-1654
  • [5] Ghazi E(2005)Interstitial lung disease in polymyositis and dermatomyositis Curr Opin Rheumatol 17 701-706
  • [6] Sontheimer RD(2005)Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis J Rheumatol 32 1719-1726
  • [7] Werth VP(2005)Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis Arthritis Rheum 52 1571-1576
  • [8] Ye S(2009)RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease Arthritis Rheum 60 2193-2200
  • [9] Chen XX(2012)Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody Arthritis Care Res (Hoboken) 64 1602-1610
  • [10] Lu XY(2012)The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM Rheumatol (United Kingdom) 51 1278-1284